Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum
- Posted on April 17, 2026
- By International Business Times
- 0 Views
- 1 min read
Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum

Shares of Hims & Hers Health Inc. climbed sharply in morning trading Friday as investors bet that potential regulatory relief on compounded peptides could strengthen the telehealth company's weight-loss offerings and broader platform growth.